Functional and Clinical Benefits of PCI in Patients With CTO

NCT01254253 — Not applicable, Unknown, 150 participants, Xijing Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Multimodality Imaging Evaluation of Functional and Clinical Benefits of Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Lesion

RegistryNCT01254253
StatusUnknown
PhaseNot applicable
Study typeInterventional; non randomized, parallel, masking: none, treatment
Enrollment150 (Estimated)
SponsorXijing Hospital (Other)
ConditionsHeart Function, Quality of Life
InterventionsPercutaneous coronary intervention, PCI (Device)
Datesstart 2008-10-01, primary completion 2010-03-01, completion 2011-11-01 (estimated), first posted 2010-12-06, last updated 2011-11-22
Locations1 site in China

Related Papers Related Patents Related Grants Related Experts
All trials for Heart Function All trials for Quality of Life All trials of Percutaneous coronary intervention, PCI

-Summary

The purpose of this study is to compare the diagnostic accuracy of hybrid imaging combining CTCA with low-dose stress-only SPECT vs. coronary angiography for detecting haemodynamic relevant coronary lesions; and second to determine the effects of PCI on cardiac perfusion, cardiac function and quality of life in patients with CTO lesion in left anterior descending (LAD) coronary artery.

Expand all sections  ·  Collapse all

+Detailed description

Noninvasive imaging modalities have shown high diagnostic accuracy in the detection of coronary artery lesions, and for the estimation of their hemodynamic relevance.Thus, noninvasive assessment of myocardial perfusion defects may be preferred for patients with chronic total occlusion (CTO).

In particular, myocardial perfusion is measured with single photon emission CT (SPECT).Multislice coronary CT angiography (CCTA) with dual-source scanners reveals the anatomic location of coronary artery disease (CAD). These two techniques assess distinct aspects of heart morphology and function parameters of the heart, and should therefore be regarded as complementary rather than competing methods.Taking this into consideration, decisions regarding whether invasive revascularization therapy is adequate or not and which strategy is the best for long-term survival cannot be supported by anatomic information alone. Therefore, noninvasive complementary imaging of structure and perfusion, in conjunction with three-dimensional (3D) image fusion, has emerged as a technique for reliable allocation of perfusion defects to their supplying coronary artery.

+Arms and interventions

ArmTypeInterventionsDescription
Group aExperimentalDevice: Percutaneous coronary intervention, PCIno severe cardiac perfusion defects
Gooup bExperimentalDevice: Percutaneous coronary intervention, PCIreversible cardiac perfusion defects
Group cExperimentalDevice: Percutaneous coronary intervention, PCIirreversible cardiac perfusion defects
  • Percutaneous coronary intervention, PCI (Device), also known as Effect, Xijing Hospital, Fourth Military Medical University: PCI was performed using standard techniques for CTO.

+Outcome measures

Primary outcomes

  • Left ventricular ejection fraction [2year]

Secondary outcomes

  • cardiac death [2year]
  • Non-fatal myocardial infarction [2 year]
  • Target lesion revascularization [2 year]
  • Angina pectoris score index [2 year]
  • Six-minute walk distance [2 year]

+Eligibility

Sex: All, ages: any to 70 Years

Inclusion Criteria:

* Patients were eligible for enrolment in this study if coronary angiography showed a CTO (at least for 3 months and confirmed by angiography and/or history of earlier MI).

Exclusion Criteria:

* Hypersensitivity to iodinated contrast agent, cardiomyopathy, non-sinus rhythm, severe valvular heart disease, NYHA functional class IV heart failure at baseline, previous coronary bypass surgery, renal insufficiency, severe lung and liver disease or cancer.

+Locations (1)

FacilityCityCountryStatus
Fourth Military Medical UniversityXi'an, ShaanxiChinaRecruiting

+Investigators

  • Feng Cao, MD, PhD, Principal investigator, Air Force Military Medical University, China